Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
accepted:
14
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
Human epidermal growth factor-2 (HER2) overexpression is an oncogenic driver in many solid tumors, including urothelial bladder cancer (UBC). In addition, activating mutations in the ERBB2 gene have been shown to play an oncogenic role similar to ERBB2 amplification. To describe and compare the frequency and nature of genomic alterations (GA) of ERBB2-altered (mutations, amplification) and ERBB2 wild-type UBC. Using a hybrid capture-based comprehensive profiling assay, 9518 UBC cases were grouped by ERBB2 alteration and evaluated for all classes of genomic alterations (GA), tumor mutational burden (TMB), microsatellite instability (MSI), genome-wide loss of heterozygosity (gLOH), and genomic mutational signature. PD-L1 expression was measured by immunohistochemistry (Dako 22C3). Categorical statistical comparisons were performed using Fisher's exact tests. A total of 602 (6.3%) UBC cases featured ERBB2 extracellular domain short variant (SV) GA (ECDmut+), 253 (2.7%) cases featured ERBB2 kinase domain SV GA (KDmut+), 866 (9.1%) cases had ERBB2 amplification (amp+), and 7797 (81.9%) cases were ERBB2 wild-type (wt). European genetic ancestry of ECDmut+ was higher than ERBB2wt. Numerous significant associations were observed when comparing GA by group. Notably among these, CDKN2A/MTAP loss were more frequent in ERBB2wt versus ECDmut+ and amp+. ERBB3 GA were more frequent in ECDmut+ and KDmut+ than ERBB2wt. TERT GA were more frequent in ECDmut+, KDmut+, and amp+ versus ERBB2wt. TOP2A amplification was significantly more common in ECDmut+ and amp+ versus ERBB2wt, and TP53 SV GA were significantly higher in ERBB2 amp+ versus ERBB2wt. Mean TMB levels were significantly higher in ECDmut+, KDmut+, and amp+ than in ERBB2wt. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBEC) signature was more frequent in ECDmut+, KDmut+, and amp+ versus ERBB2wt. No significant differences were observed in PD-L1 status between groups, while gLOH-high status was more common in amp+ versus ERBB2wt. MSI-high status was more frequent in KDmut+ versus ERBB2wt, and in ERBB2wt than in amp+. We noted important differences in co-occurring GA in ERBB2-altered (ECDmut+, KDmut+, amp+) versus ERBB2wt UBC, as well as higher mean TMB and higher APOBEC mutational signature in the ERBB2-altered groups. Our results can help refine future clinical trial designs and elucidate possible response and resistance mechanisms for ERBB2-altered UBC.
Sections du résumé
BACKGROUND
BACKGROUND
Human epidermal growth factor-2 (HER2) overexpression is an oncogenic driver in many solid tumors, including urothelial bladder cancer (UBC). In addition, activating mutations in the ERBB2 gene have been shown to play an oncogenic role similar to ERBB2 amplification.
OBJECTIVE
OBJECTIVE
To describe and compare the frequency and nature of genomic alterations (GA) of ERBB2-altered (mutations, amplification) and ERBB2 wild-type UBC.
PATIENTS AND METHODS
METHODS
Using a hybrid capture-based comprehensive profiling assay, 9518 UBC cases were grouped by ERBB2 alteration and evaluated for all classes of genomic alterations (GA), tumor mutational burden (TMB), microsatellite instability (MSI), genome-wide loss of heterozygosity (gLOH), and genomic mutational signature. PD-L1 expression was measured by immunohistochemistry (Dako 22C3). Categorical statistical comparisons were performed using Fisher's exact tests.
RESULTS
RESULTS
A total of 602 (6.3%) UBC cases featured ERBB2 extracellular domain short variant (SV) GA (ECDmut+), 253 (2.7%) cases featured ERBB2 kinase domain SV GA (KDmut+), 866 (9.1%) cases had ERBB2 amplification (amp+), and 7797 (81.9%) cases were ERBB2 wild-type (wt). European genetic ancestry of ECDmut+ was higher than ERBB2wt. Numerous significant associations were observed when comparing GA by group. Notably among these, CDKN2A/MTAP loss were more frequent in ERBB2wt versus ECDmut+ and amp+. ERBB3 GA were more frequent in ECDmut+ and KDmut+ than ERBB2wt. TERT GA were more frequent in ECDmut+, KDmut+, and amp+ versus ERBB2wt. TOP2A amplification was significantly more common in ECDmut+ and amp+ versus ERBB2wt, and TP53 SV GA were significantly higher in ERBB2 amp+ versus ERBB2wt. Mean TMB levels were significantly higher in ECDmut+, KDmut+, and amp+ than in ERBB2wt. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBEC) signature was more frequent in ECDmut+, KDmut+, and amp+ versus ERBB2wt. No significant differences were observed in PD-L1 status between groups, while gLOH-high status was more common in amp+ versus ERBB2wt. MSI-high status was more frequent in KDmut+ versus ERBB2wt, and in ERBB2wt than in amp+.
CONCLUSIONS
CONCLUSIONS
We noted important differences in co-occurring GA in ERBB2-altered (ECDmut+, KDmut+, amp+) versus ERBB2wt UBC, as well as higher mean TMB and higher APOBEC mutational signature in the ERBB2-altered groups. Our results can help refine future clinical trial designs and elucidate possible response and resistance mechanisms for ERBB2-altered UBC.
Identifiants
pubmed: 38570422
doi: 10.1007/s11523-024-01056-x
pii: 10.1007/s11523-024-01056-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654 .
doi: 10.3322/caac.21654
pubmed: 33433946
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–30. https://doi.org/10.1056/NEJMoa2002788 .
doi: 10.1056/NEJMoa2002788
pubmed: 32945632
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8.
doi: 10.1200/JCO.2005.07.757
pubmed: 16034041
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22. https://doi.org/10.1016/S1470-2045(17)30065-7 .
doi: 10.1016/S1470-2045(17)30065-7
pubmed: 28131785
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30:970–6. https://doi.org/10.1093/annonc/mdz127 .
doi: 10.1093/annonc/mdz127
pubmed: 31050707
pmcid: 6594457
Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020;8: e001246. https://doi.org/10.1136/jitc-2020-001246 .
doi: 10.1136/jitc-2020-001246
pubmed: 33037118
pmcid: 7549450
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474–85. https://doi.org/10.1200/JCO.20.03489 .
doi: 10.1200/JCO.20.03489
pubmed: 33929895
pmcid: 8315301
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee J-L, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125–35. https://doi.org/10.1056/NEJMoa2035807 .
doi: 10.1056/NEJMoa2035807
pubmed: 33577729
pmcid: 8450892
Yu EY, Petrylak DP, O’Donnell PH, Lee J-L, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872–82. https://doi.org/10.1016/S1470-2045(21)00094-2 .
doi: 10.1016/S1470-2045(21)00094-2
pubmed: 33991512
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961–71.
doi: 10.1056/NEJMoa2308849
pubmed: 37870920
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778–89. https://doi.org/10.1056/NEJMoa2309863 .
doi: 10.1056/NEJMoa2309863
pubmed: 37870949
Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34(Suppl 2):S1340. https://doi.org/10.1016/j.annonc.2023.10.106 .
doi: 10.1016/j.annonc.2023.10.106
Gan K, Gao Y, Liu K, Xu B, Qin W. The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta-analysis and a bioinformatic analysis. Front Oncol. 2021;11: 653491. https://doi.org/10.3389/fonc.2021.653491 .
doi: 10.3389/fonc.2021.653491
pubmed: 34540657
pmcid: 8440975
Grivas PD, Day M, Hussain M. Urothelial carcinomas: a focus on human epidermal receptors signaling. Am J Transl Res. 2011;3:362–73.
pubmed: 21904656
pmcid: 3158738
Koshkin VS, O’Donnell P, Yu EY, Grivas P. Systematic review: targeting HER2 in Bladder Cancer. Bladder Cancer. 2019;5:1–12. https://doi.org/10.3233/BLC-180196 .
doi: 10.3233/BLC-180196
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle invasive bladder cancer. Cell. 2017;171:540-556.e25. https://doi.org/10.1016/j.cell.2017.09.007 .
doi: 10.1016/j.cell.2017.09.007
pubmed: 28988769
pmcid: 5687509
Ross JS, Wang K, Khaira D, Ali SM, Fisher HAG, Mian B, et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016;122:702–11. https://doi.org/10.1002/cncr.29826 .
doi: 10.1002/cncr.29826
pubmed: 26651075
Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014;20:68–75. https://doi.org/10.1158/1078-0432.CCR-13-1992 .
doi: 10.1158/1078-0432.CCR-13-1992
pubmed: 24192927
Galsky MD, Del Conte G, Foti S, Yu EY, Machiels J-PH, Doger B, et al. Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J Clin Oncol. 2022;40:438–438. https://doi.org/10.1200/JCO.2022.40.6_suppl.438 .
doi: 10.1200/JCO.2022.40.6_suppl.438
Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol. 2016;34:2165–71. https://doi.org/10.1200/JCO.2015.66.3047 .
doi: 10.1200/JCO.2015.66.3047
pubmed: 27044931
pmcid: 5569685
Bryce AH, Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, et al. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): preliminary data from MyPathway. J Clin Oncol. 2017;35(Suppl 6):348–348. https://doi.org/10.1200/JCO.2017.35.6_suppl.348 .
doi: 10.1200/JCO.2017.35.6_suppl.348
Connolly R, Wang V, Hyman D, Grivas P, Mitchell E, Wright J, et al. 553P activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophageal HER2-amplified tumours: results of the NCI-MATCH trial (EAY131) subprotocol. Ann Oncol. 2020;31(Suppl 4):S479–80. https://doi.org/10.1016/j.annonc.2020.08.667 .
doi: 10.1016/j.annonc.2020.08.667
Powles T, Yu EY, Iyer G, Campbell MT, Loriot Y, De Santis M, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41(Suppl 6):TPS594. https://doi.org/10.1200/JCO.2023.41.6_suppl.TPS594
RemeGen Co., Ltd. A study of RC48-ADC combined with toripalimab for first-line treatment of urothelial carcinoma. ClinicalTrials.gov identifier: NCT05302284. Updated December 18, 2023. Accessed 20 Dece 2023. https://clinicaltrials.gov/study/NCT05302284
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21:815–9. https://doi.org/10.1093/annonc/mdp488 .
doi: 10.1093/annonc/mdp488
pubmed: 19889613
Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350–7. https://doi.org/10.1016/j.eururo.2011.05.035 .
doi: 10.1016/j.eururo.2011.05.035
pubmed: 21640482
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3:224–37. https://doi.org/10.1158/2159-8290.CD-12-0349 .
doi: 10.1158/2159-8290.CD-12-0349
pubmed: 23220880
Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 2017;8:114371–92. https://doi.org/10.18632/oncotarget.22825 .
doi: 10.18632/oncotarget.22825
pubmed: 29371993
pmcid: 5768410
Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4:844–52. https://doi.org/10.1002/cam4.432 .
doi: 10.1002/cam4.432
pubmed: 25720673
pmcid: 4472207
Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch Int J Pathol. 2015;466:703–10. https://doi.org/10.1007/s00428-015-1729-4 .
doi: 10.1007/s00428-015-1729-4
Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014;27:758–64. https://doi.org/10.1038/modpathol.2013.201 .
doi: 10.1038/modpathol.2013.201
pubmed: 24186136
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-Trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7. https://doi.org/10.1200/JCO.2018.77.9777 .
doi: 10.1200/JCO.2018.77.9777
pubmed: 29989854
pmcid: 6366814
de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol Ther. 2014;15:1239–47. https://doi.org/10.4161/cbt.29687 .
doi: 10.4161/cbt.29687
pubmed: 24971884
pmcid: 4128866
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31. https://doi.org/10.1038/nbt.2696 .
doi: 10.1038/nbt.2696
pubmed: 24142049
pmcid: 5710001
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. https://doi.org/10.1186/s13073-017-0424-2 .
doi: 10.1186/s13073-017-0424-2
pubmed: 28420421
pmcid: 5395719
Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, et al. A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn. 2019;21:1053–66. https://doi.org/10.1016/j.jmoldx.2019.06.011 .
doi: 10.1016/j.jmoldx.2019.06.011
pubmed: 31445211
pmcid: 7807551
Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018;14:e1005965. https://doi.org/10.1371/journal.pcbi.1005965 .
doi: 10.1371/journal.pcbi.1005965
pubmed: 29415044
pmcid: 5832436
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101. https://doi.org/10.1038/s41586-020-1943-3 .
doi: 10.1038/s41586-020-1943-3
pubmed: 32025018
pmcid: 7054213
Newberg J, Connelly C, Frampton G. Abstract 1599: determining patient ancestry based on targeted tumor comprehensive genomic profiling. Cancer Res. 2019;79:1599. https://doi.org/10.1158/1538-7445.AM2019-1599 .
doi: 10.1158/1538-7445.AM2019-1599
Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69:384–8. https://doi.org/10.1016/j.eururo.2015.01.014 .
doi: 10.1016/j.eururo.2015.01.014
pubmed: 25636205
Wang H, Jiang Y, Jin H, Wang C. ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients. Front Oncol. 2022;12:1012138. https://doi.org/10.3389/fonc.2022.1012138 .
doi: 10.3389/fonc.2022.1012138
pubmed: 36172165
pmcid: 9511046
Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, et al. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology. 2018;8: e1512942. https://doi.org/10.1080/2162402X.2018.1512942 .
doi: 10.1080/2162402X.2018.1512942
pubmed: 30546951
pmcid: 6287794
Kwon HJ, Park Y, Nam SK, Kang E, Kim K-K, Jeong I, et al. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: their association with response to trastuzumab-based treatment. Cancer Med. 2023;12:10371–84. https://doi.org/10.1002/cam4.5769 .
doi: 10.1002/cam4.5769
pubmed: 36916290
pmcid: 10225221
Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, et al. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021;5:23. https://doi.org/10.1038/s41698-021-00163-6 .
doi: 10.1038/s41698-021-00163-6
pubmed: 33742063
pmcid: 7979716
Pal SK, Agarwal N, Choueiri TK, Stephens PJ, Ross JS, Miller VA, et al. Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC). Ann Oncol. 2017;28(Suppl 5):V297. https://doi.org/10.1093/annonc/mdx371.004 .
doi: 10.1093/annonc/mdx371.004
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet. 2016;387:1909–20. https://doi.org/10.1016/S0140-6736(16)00561-4 .
doi: 10.1016/S0140-6736(16)00561-4
pubmed: 26952546
pmcid: 5480242
Galsky MD, Saci A, Szabo PM, Azrilevich A, Horak C, Lambert A, et al. Impact of tumor mutation burden on nivolumab efficacy in second line urothelial carcinoma patients: exploratory analysis of the phase ii checkmate 275 study. Ann Oncol. 2017;28(Suppl 5):V296–7. https://doi.org/10.1093/annonc/mdx371.003 .
doi: 10.1093/annonc/mdx371.003
Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2014;27:271–80. https://doi.org/10.1038/modpathol.2013.135 .
doi: 10.1038/modpathol.2013.135
pubmed: 23887298
Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003;107:764–72. https://doi.org/10.1002/ijc.11477 .
doi: 10.1002/ijc.11477
pubmed: 14566826
Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide analysis of non-coding regulatory mutations in cancer. Nat Genet. 2014;46:1160–5. https://doi.org/10.1038/ng.3101 .
doi: 10.1038/ng.3101
pubmed: 25261935
pmcid: 4217527
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110:6021–6. https://doi.org/10.1073/pnas.1303607110 .
doi: 10.1073/pnas.1303607110
pubmed: 23530248
pmcid: 3625331
Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen S, et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015;347:1006–10. https://doi.org/10.1126/science.1260200 .
doi: 10.1126/science.1260200
pubmed: 25722414
pmcid: 4640672
Arnoff TE, El-Deiry WS. CDKN1A/p21WAF1, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. Am J Cancer Res. 2021;11:5452–71.
pubmed: 34873472
pmcid: 8640812
Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, et al. Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma. JAMA Oncol. 2021;7:1–8. https://doi.org/10.1001/jamaoncol.2021.3441 .
doi: 10.1001/jamaoncol.2021.3441
pmcid: 8391778
Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115: 102530. https://doi.org/10.1016/j.ctrv.2023.102530 .
doi: 10.1016/j.ctrv.2023.102530
pubmed: 36898352
Bou Zerdan M, Bratslavsky G, Jacob J, Ross J, Huang R, Basnet A. Urothelial bladder cancer: genomic alterations in fibroblast growth factor receptor. Mol Diagn Ther. 2023;27:475–85. https://doi.org/10.1007/s40291-023-00647-0 .
doi: 10.1007/s40291-023-00647-0
pubmed: 37195586
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22. https://doi.org/10.1038/nature12965 .
Nagl NG, Patsialou A, Haines DS, Dallas PB, Beck GR, Moran E. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005;65:9236–44. https://doi.org/10.1158/0008-5472.CAN-05-1225 .
doi: 10.1158/0008-5472.CAN-05-1225
pubmed: 16230384
Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020;8: e000438. https://doi.org/10.1136/jitc-2019-000438 .
doi: 10.1136/jitc-2019-000438
pubmed: 32111729
pmcid: 7057434
Jana S, Brahma S, Arora S, Wladyka CL, Hoang P, Blinka S, et al. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression. Cancer Cell. 2023;41:853-870.e13. https://doi.org/10.1016/j.ccell.2023.03.021 .
doi: 10.1016/j.ccell.2023.03.021
pubmed: 37084735
Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26:5433–8. https://doi.org/10.1038/sj.onc.1210611 .
doi: 10.1038/sj.onc.1210611
pubmed: 17694084
Pegoraro G, Kubben N, Wickert U, Göhler H, Hoffmann K, Misteli T. Ageing-related chromatin defects through loss of the NURD complex. Nat Cell Biol. 2009;11:1261–7. https://doi.org/10.1038/ncb1971 .
doi: 10.1038/ncb1971
pubmed: 19734887
pmcid: 2779731
Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J. 2010;29:3130–9. https://doi.org/10.1038/emboj.2010.188 .
doi: 10.1038/emboj.2010.188
pubmed: 20693977
pmcid: 2944064
Chakrabarty A, Sanchez V, Kuba M, Rinehart C, Arteaga C. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012;109:2718–23.
doi: 10.1073/pnas.1018001108
pubmed: 21368164
Serra V, Scaltriti M, Prudkin L, Eichhorn P, Ibrahim Y, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30:2547–57.
doi: 10.1038/onc.2010.626
pubmed: 21278786
pmcid: 3107390
Grivas P, Day K, Karatsinides A, Paul A, Shakir N, Owainati I, et al. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Mol Med. 2013;19:367–76. https://doi.org/10.2119/molmed.2013.00108 .
doi: 10.2119/molmed.2013.00108
pubmed: 24166682
pmcid: 3883970
Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A 3rd, Broses L, et al. Molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer. Bladder Cancer. 2018;4:77–90. https://doi.org/10.3233/BLC-170144 .
doi: 10.3233/BLC-170144
pubmed: 29430509
pmcid: 5798519
Junttila T, Akita R, Parsons K, Fields C, Lewis Phillips G, Friedman L, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC0941. Cancer Cell. 2009;15:429–40.
doi: 10.1016/j.ccr.2009.03.020
pubmed: 19411071
Agus D, Akita R, Fox W, Lewis G, Higgins B, Pisacane P, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2:127–37.
doi: 10.1016/S1535-6108(02)00097-1
pubmed: 12204533